56 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
1
Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1.
Harvard University
4
Discovery ofa-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Dongguk University
37
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Baylor College of Medicine
4
Inhibitors of Mutant IDH for the Treatment of Cancer.
Therachem Research Medilab (India)
61
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Baylor College of Medicine
6
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.
Baylor College of Medicine
8
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.
TBA
4
Comprehensive exploration of isocitrate dehydrogenase (IDH) mutations: Tumorigenesis, drug discovery, and covalent inhibitor advances.
Naval Medical University
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
66
Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.
Nanjing University of Chinese Medicine
19
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect.
Children's Hospital Affiliated to Zhengzhou University
10
Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.
Chongqing Medical University
17
Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities.
Zhengzhou University
33
Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.
China Pharmaceutical University
40
Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.
Chinese Academy of Sciences
12
Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors.
University of Oxford
26
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.
Novartis Institutes For Biomedical Research
2
Accelerating Drug Discovery: Synthesis of Complex Chemotypes via Multicomponent Reactions.
Atavistik Bio
83
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Indian Institute of Technology (B.H.U.)
25
Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors.
Merck
95
Discovery and Optimization of 2
National Center For Advancing Translational Sciences
2
Withanolides from dietary tomatillo suppress HT1080 cancer cell growth by targeting mutant IDH1.
Shenyang Pharmaceutical University
109
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
University of Manchester
21
Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors.
Shandong Provincial Hospital Affiliated To Shandong University
1
Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor.
Guizhou Medcial University
26
Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
Chinese Academy of Sciences
17
Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening.
Huazhong Agricultural University
70
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Forma Therapeutics
20
Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells.
Meyer Cancer Center
14
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Agios Pharmaceuticals
10
Flavipesines A and B and Asperchalasines E-H: Cytochalasans and Merocytochalasans from
Huazhong University of Science and Technology
30
Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
Zhejiang University
20
Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Shanghai Haihe Pharmaceutical
13
Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315.
TBA
14
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Forma Therapeutics
73
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
China Pharmaceutical University
14
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Agios Pharmaceuticals
16
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Novartis Institutes For Biomedical Research
9
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
China Pharmaceutical University
40
Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
Shanghai Haihe
14
Lucky Switcheroo: Dramatic Potency and Selectivity Improvement of Imidazoline Inhibitors of Human Carbonic Anhydrase VII.
Saint Petersburg State University
67
Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH).
National Center For Advancing Translational Sciences
79
METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF
Insilico Medicine IP
9
Derivatives of 4-aminoantipyrine as anti-Alzheimers butyrylcholinesterase inhibitors
Individual
97
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
University of Illinois At Chicago
149
1,2-substituted cyclopentanes as orexin receptor antagonists
Takeda Pharmaceutical
14
Cardiac glycoside analogs and their use in methods for inhibition of viral infection
The John Hopkins University
15
Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
Nerviano Medical Sciences
7
Novel synthesis of dihydropyrimidines for a-glucosidase inhibition to treat type 2 diabetes: in vitro biological evaluation and in silico docking.
Comsats Institute of Information Technology